R&G PharmaStudies Co. Ltd. A (301333) - Total Assets
Based on the latest financial reports, R&G PharmaStudies Co. Ltd. A (301333) holds total assets worth CN¥2.40 Billion CNY (≈ $351.41 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
R&G PharmaStudies Co. Ltd. A - Total Assets Trend (2019–2025)
This chart illustrates how R&G PharmaStudies Co. Ltd. A's total assets have evolved over time, based on quarterly financial data. Also see R&G PharmaStudies Co. Ltd. A (301333) market capitalisation for the company's overall valuation and market capitalisation.
R&G PharmaStudies Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2025)
R&G PharmaStudies Co. Ltd. A's total assets of CN¥2.40 Billion consist of 89.8% current assets and 10.2% non-current assets. Review 301333 current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 47.0% |
| Accounts Receivable | CN¥133.47 Million | 5.6% |
| Inventory | CN¥59.02 Million | 2.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥16.25 Million | 0.7% |
| Goodwill | CN¥85.60 Million | 3.6% |
Asset Composition Trend (2019–2025)
This chart illustrates how R&G PharmaStudies Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 301333 share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: R&G PharmaStudies Co. Ltd. A's current assets represent 89.8% of total assets in 2025, an increase from 89.7% in 2019.
- Cash Position: Cash and equivalents constituted 47.0% of total assets in 2025, down from 61.3% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 4.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 5.6% of total assets.
R&G PharmaStudies Co. Ltd. A Competitors by Total Assets
Key competitors of R&G PharmaStudies Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
R&G PharmaStudies Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.01 | 5.87 | 2.44 |
| Quick Ratio | 5.86 | 5.67 | 2.24 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.80 Billion | CN¥1.73 Billion | CN¥351.81 Million |
R&G PharmaStudies Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between R&G PharmaStudies Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.18 |
| Latest Market Cap to Assets Ratio | 0.38 |
| Asset Growth Rate (YoY) | 2.7% |
| Total Assets | CN¥2.40 Billion |
| Market Capitalization | $909.45 Million USD |
Valuation Analysis
Below Book Valuation: The market values R&G PharmaStudies Co. Ltd. A's assets below their book value (0.38x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: R&G PharmaStudies Co. Ltd. A's assets grew by 2.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for R&G PharmaStudies Co. Ltd. A (2019–2025)
The table below shows the annual total assets of R&G PharmaStudies Co. Ltd. A from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.40 Billion ≈ $351.14 Million |
+2.71% |
| 2024-12-31 | CN¥2.34 Billion ≈ $341.86 Million |
+12.65% |
| 2023-12-31 | CN¥2.07 Billion ≈ $303.46 Million |
+10.13% |
| 2022-12-31 | CN¥1.88 Billion ≈ $275.55 Million |
+177.96% |
| 2021-12-31 | CN¥677.47 Million ≈ $99.14 Million |
+26.31% |
| 2020-12-31 | CN¥536.36 Million ≈ $78.49 Million |
+20.03% |
| 2019-12-31 | CN¥446.86 Million ≈ $65.39 Million |
-- |
About R&G PharmaStudies Co. Ltd. A
R&G PharmaStudies Co., Ltd. operates as a clinical trial outsourcing service provider in China and internationally. It offers drug clinical research and development integrated services. The company's services include clinical trial operation, clinical trial site management, biological sample testing, data management and statistical analysis, clinical trial consulting, and clinical pharmacology se… Read more